Clinical Trials Using Adavosertib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Adavosertib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-13 of 13
  • Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
    Location: 1197 locations

  • Testing AZD1775 in Advanced Solid Tumors that have a Mutation called SETD2

    This phase II trial studies how well adavosertib works in treating patients with SETD2-deficient solid tumors that have spread to other places in the body (advanced / metastatic). Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 22 locations

  • Adavosertib before Surgery in Treating Patients with Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    This pilot early phase I trial studies how adavosertib affects the tumor deoxyribonucleic acid (DNA) of patients undergoing surgery for high grade (fast growing or aggressive) ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body (advanced). Certain characteristics in the DNA of these patients may affect how well they respond to treatment. Learning how adavosertib affects DNA in tumor cells may help doctors plan effective treatment.
    Location: 7 locations

  • MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

    This phase II trial studies molecular profiling-based assignment of cancer therapy (MPACT) in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Adavosertib, everolimus, and trametinib are drugs that each target a specific variation in tumors by blocking different proteins needed for cell growth. Veliparib blocks an enzyme that helps repair deoxyribonucleic acid (DNA) damaged by chemotherapy, which may help chemotherapy drugs work better. It is not yet known whether testing patients for variations in their tumor and assigning treatment targeting the variation is more effective than standard non-targeted therapy in treating advanced solid tumors.
    Location: 7 locations

  • Testing AZD1775 inC combination with Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

    This phase I trial studies the side effects and best dose of adavosertib when given together with external beam radiation therapy and cisplatin in treating patients with cervical, vaginal, or uterine cancer. Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. External beam radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving adavosertib, external beam radiation therapy, and cisplatin may work better in treating patients with cervical, vaginal, or uterine cancer.
    Location: 6 locations

  • To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

    This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (AZD6738) and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib [AZD1775]) in second or third line setting in patients with Triple-negative breast cancer (TNBC) prospectively stratified by presence / absence of qualifying tumour mutation in genes involved in the homologous recombination repair (HRR) pathway. Treatment arms are olaparib monotherapy, olaparib+AZD6738 and olaparib+adavosertib. The study subject population will be divided into Stratum A, Stratum B, and Stratum C. Due to the different schedules of administration of each of the treatment options as well as their different toxicity profiles, the study is not blinded. Study has two stage consent process- stage 1 consent (molecular screening for HRR defects) and stage 2 consent (main study). Patients with TNBC and with known qualifying BRCAm, non BRCAm HRRm and non HRRm status will be offered the option of consenting to the main part of the study within the 28-day screening period. Following the ISRC meeting on 17 April 2019 a recommendation was made to close the adavosertib+olaparib treatment arm across all biomarker strata. Patients receiving treatment with adavosertib+olaparib treatment were offered the opportunity to continue treatment on olaparib monotherapy at the approved dose (300 mg bd). Following the closure of this arm the total number of patients randomised will be lower (approximately 350 patients). Approximately 300 patients will be randomised (using randomisation ratio 1:1) to 2 ongoing treatment arms plus an additional 47 patients to a 3rd arm (olaparib+adavosertib) prior to the arm being discontinued.
    Location: 4 locations

  • Adavosertib in Treating Patients with Recurrent Uterine Serous Carcinoma or Uterine Carcinosarcoma

    This phase II trial studies how well adavosertib works in treating patients with uterine serous cancer or uterine carcinosarcoma that has come back (recurrent). Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Adavosertib with or without Olaparib in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    This phase II trial studies how well adavosertib with or without olaparib work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Adavosertib and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • A Phase II Trial of AZD1775 plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

    This phase II trial studies how WEE1 Inhibitor AZD1775, carboplatin, and paclitaxel work in treating patients with squamous cell lung cancer that has spread to other places in the body (metastatic) and usually cannot be cured or controlled with treatment (advanced), or has come back (recurrent). WEE1 inhibitor AZD1775 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving WEE1 inhibitor AZD1775 together with carboplatin and paclitaxel may be an effective treatment for squamous cell lung cancer.
    Location: 2 locations

  • Testing the Sequential Combination of the Anti-cancer Drugs Olaparib followed by Adavosertib (AZD1775) in Patients with Advanced Solid Tumors with Selected Mutations and PARP Resistance, STAR Study

    This phase I trial studies the side effects and best dose of adavosertib when given together with olaparib in treating patients with solid tumors that have spread to other places in the body (advanced) with selected mutations. Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Giving olaparib and adavosertib one after the other may shrink or stabilize advanced solid tumors as successfully as using them together, with fewer side effects.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients with Incurable Esophageal and Gastroesophageal Junction Cancers

    This phase I trial investigates the side effects and best dose of adavosertib and how well it works when given in combination with radiation therapy in treating patients with esophageal or gastroesophageal junction cancer for which no treatment is currently available (incurable). Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving adavosertib together with radiation therapy kill more tumor cells than radiation therapy alone in treating patients with esophageal and gastroesophageal junction cancer.
    Location: Location information is not yet available.

  • AZD1775 in Treating Patients with Advanced Refractory Solid Tumors with CCNE1 Amplification

    This phase II trial studies how well AZD1775 works in treating patients with solid tumors with CCNE1 amplification that have spread to other places in the body (advanced) and do not respond to treatment (refractory). AZD1775 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 8 locations

  • Olaparib with and without AZD1775, AZD5363, and AZD2014 in Treating Patients with Advanced Solid Tumors

    This phase II trial studies how well olaparib works with and without other targeted therapies in treating patients with solid tumors that have spread to other places in the body. Olaparib, WEE1 inhibitor AZD1775 (AZD1775), Akt serine / threonine-specific protein kinase (Akt) inhibitor AZD5363 (AZD5363), and mammalian target of rapamycin (mTor) kinase inhibitor AZD2014 (AZD2014) may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and repair. It is not yet known if giving olaparib alone or in combination with AZD1775, AZD5363, or AZD2014 will work better in treating patients with solid tumors that have spread to other places in the body.
    Location: 4 locations